Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus (OLLTT)
An Open-Label, Long-Term Treatment Study to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane With Subjective Tinnitus
Sponsor: Merz Pharmaceuticals GmbH
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Merz Pharmaceuticals GmbH
- Habitual Snoring · Phase PHASE2 · Nov 2012
- Alzheimer's Disease · Phase PHASE4 · Jun 2009
- Blepharospasm · Phase PHASE2 · Feb 2008
- Multiple Sclerosis · Phase PHASE2
More terminations from Merz Pharmaceuticals GmbH
A PHASE3 clinical study on Subjective Tinnitus, this trial is terminated or withdrawn. The trial is conducted by Merz Pharmaceuticals GmbH and has accumulated 8 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Jan 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merz Pharmaceuticals GmbH
For direct contact, visit the study record on ClinicalTrials.gov .